Related Experiment Videos
[Systemic thrombolytic therapy of myocardial infarction]
Insights
Systemic thrombolytic therapy effectively treats myocardial infarction within 6 hours. Immobilized streptokinase offers similar benefits to native drugs but with fewer side effects.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Myocardial infarction (MI) remains a leading cause of mortality.
- Systemic thrombolytic therapy is a critical treatment for acute MI.
- Optimizing thrombolytic regimens to improve efficacy and reduce side effects is crucial.
Purpose of the Study:
- To compare the clinical effectiveness and safety of immobilized streptokinase versus native thrombolytic drugs in patients with large-focal myocardial infarction.
- To evaluate the impact of early initiation of systemic thrombolytic therapy on MI outcomes.
Main Methods:
- A comparative study involving 67 patients with large-focal myocardial infarction.
- Patients received either immobilized streptokinase (n=37) or native thrombolytic drugs (streptokinase or urokinase, n=30).
- Therapy was initiated within 6 hours of symptom onset.
Main Results:
- Systemic thrombolytic therapy initiated within 6 hours favorably impacted MI course.
- Significant reductions in protracted disease, arrhythmias, and rapid elimination of congestive heart failure were observed.
- Both regimens were clinically equivalent in efficacy.
- Immobilized streptokinase demonstrated considerably reduced rates of specific side effects.
Conclusions:
- Early systemic thrombolytic therapy is beneficial for managing myocardial infarction.
- Immobilized streptokinase is an effective and safer alternative to native thrombolytic drugs, with comparable clinical outcomes and fewer side effects.
Abstract:
Systemic thrombolytic therapy was given to 67 patients with large-focal myocardial infarction: immobilized streptokinase (streptodecase) was administered to 37 patients, and native thrombolytic drugs (streptokinase or urokinase), to 30 patients. Systemic thrombolytic therapy initiated within 6 hours of the attack was shown to affect favorably the course of myocardial infarction, as manifested in a significant reduction of the incidence of protracted disease and arrhythmias, and rapid elimination of congestive heart failure. The two regimens being equally effective in clinical terms, immobilized streptokinase was associated with considerably reduced rates of specific side-effects common to thrombolytic therapy.